Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Payables (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Payables for 6 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 72.3% to $17.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.3 million, a 72.3% increase, with the full-year FY2025 number at $17.3 million, up 72.3% from a year prior.
  • Payables was $17.3 million for Q4 2025 at PROCEPT BioRobotics, up from $11.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $17.3 million in Q4 2025 to a low of $2.0 million in Q4 2021.
  • A 5-year average of $9.7 million and a median of $10.1 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: soared 362.84% in 2022, then dropped 26.31% in 2025.
  • PROCEPT BioRobotics' Payables stood at $2.0 million in 2021, then skyrocketed by 362.84% to $9.4 million in 2022, then soared by 43.74% to $13.5 million in 2023, then decreased by 25.68% to $10.0 million in 2024, then soared by 72.3% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Payables are $17.3 million (Q4 2025), $11.1 million (Q3 2025), and $11.8 million (Q2 2025).